Clinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1

Bondarenko, I.Sezer, A.Kılıçkap, SaadettinGümüş, M.Özgüroğlu, M.Gogishvili, M.urk, H. M.Cicin, I.2021-11-152021-11-152021Bondarenko, I., Sezer, A., Kilickap, S., Gümüş, M., Özgüroğlu, M., Gogishvili, M., ... & Rietschel, P. (2021). FP04. 03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1. Journal of Thoracic Oncology, 16(10), S951.1556-08641556-1380https://doi.org/10.1016/j.jtho.2021.08.217https://hdl.handle.net/20.500.12713/2235[No Abstract Available]eninfo:eu-repo/semantics/closedAccessClinical benefit of first-line cemiplimab in patients with locally advanced NSCLC: subgroup analysis from EMPOWER-lung 1Other1610S951S951WOS:000709606500217Q1